TriSalus Life Sciences (TLSI) Stock News

TriSalus Life Sciences (Nasdaq: TLSI), an oncology company focused on integrating novel delivery technology with standard therapies for solid tumors, announced its participation in two upcoming investor conferences in September 2025.

CEO Mary Szela and CFO David Patience will attend the Cantor Global Healthcare Conference on September 5, featuring a fireside chat at 9:35 a.m. ET, and the Lake Street Capital Markets Best Ideas Growth Conference on September 11. Both events will take place in New York, NY. A webcast replay will be available for 90 days on the company's investor website.

TriSalus Life Sciences (Nasdaq: TLSI) reported strong Q2 2025 financial results, with revenue reaching $11.2 million, representing a 52% year-over-year and 22% quarter-over-quarter growth. The company successfully launched TriNav FLX, expanding its PEDD portfolio with enhanced vessel navigation capabilities.

Key financial metrics include 84% gross margins, operating losses of $7.3 million (improved from $8.2M in 2024), and cash position of $26.5 million. The company reiterated its full-year revenue growth guidance of at least 50% and expects to reach positive adjusted EBITDA in H1 2026.

TriSalus Life Sciences (Nasdaq: TLSI) has published clinical data evaluating its proprietary Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization using the TriNav® Infusion System. The retrospective single-center study demonstrated promising results in treating symptomatic thyroid disease.

The study of 22 patients showed significant outcomes, including 100% technical and clinical success, 71% of hyperthyroid patients achieving normal thyroid function, and a 73% mean reduction in thyroid gland volume at 6 months. No major complications were reported, with only mild post-procedure symptoms resolving within two weeks.

A multi-institutional registry study (PROTECT, NCT06868459) has been initiated to further validate these findings in a broader setting.

TriSalus Life Sciences (Nasdaq: TLSI), a company focused on improving solid tumor treatment outcomes through innovative drug delivery, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference.

CEO and President Mary Szela and CFO David Patience will deliver a presentation on August 13, 2025, at 9:00 a.m. ET. The presentation will be available via live webcast, with a replay accessible for 90 days on the company's investor website.

TriSalus Life Sciences (Nasdaq: TLSI), a company focused on improving solid tumor treatment outcomes through innovative drug delivery and immunotherapy, has scheduled its Q2 2025 financial results conference call for Tuesday, August 12, 2025, at 4:30 PM ET.

The company will release its financial results for the quarter ended June 30, 2025, before the call. Interested participants can register online to receive dial-in details and a personal PIN. The event will be webcast live on TriSalus' investor relations website, with a replay available afterward.

TriSalus Life Sciences (Nasdaq: TLSI) has successfully completed its exchange offer and consent solicitation for Preferred Stock, which expired on July 23, 2025. Under the offer terms, preferred shareholders could exchange each share for 3.3 shares of common stock.

The exchange offer saw strong participation with 98.82% of outstanding preferred shares being tendered. Settlement is expected by August 1, 2025. Following sufficient shareholder approval, remaining preferred shares will be automatically converted to common stock at a rate 11.3% lower than the offered rate.

TriSalus Life Sciences (Nasdaq: TLSI) has initiated an exchange offer and consent solicitation for its Series A Convertible Preferred Stock. The company aims to simplify its capital structure by allowing preferred stockholders to exchange their shares for common stock. Each preferred share can be exchanged based on its accrued value divided by $4.00 per share, with up to 11,860,206 common shares available for the exchange.

The company has secured support from holders of approximately 55% of outstanding preferred stock through tender agreements. The offer expires on July 23, 2025. Additionally, TriSalus is seeking consent to amend terms allowing automatic conversion of remaining preferred shares at a 11.3% lower exchange ratio after the offer closes.

TriSalus Life Sciences (NASDAQ: TLSI) has launched the TriNav FLX Infusion System, an enhanced version of their medical device portfolio for treating solid tumors. The new system features improved trackability with twice the length of flexible material at the distal end, enabling better navigation through complex blood vessels. In benchtop testing, TriNav FLX showed a 28% reduction in force during navigation compared to the standard design. The device maintains the same Pressure-Enabled Drug Delivery (PEDD) benefits while offering interventional radiologists more options for patient treatment. Importantly, TriNav FLX is eligible for reimbursement under HCPCS codes C8004 for simulation/mapping and C9797 for treatment procedures, supporting both planning and delivery in radioembolization procedures.

TriSalus Life Sciences (NASDAQ: TLSI) has appointed David B. Patience as its new Chief Financial Officer, effective July 1, 2025. Patience, who previously served as CFO at Accelerate Diagnostics, succeeds James Young, who stepped down for personal reasons on May 30, 2025. During the transition period, Dan Giordano, Vice President of Finance, will serve as acting CFO. Patience brings significant experience in capital markets, strategic product portfolio planning, and M&A analysis from his previous roles at Morgan Stanley's Investment Banking Division, Continental Advisors, and Nuveen Investments. He holds a BS in Business Administration from the University of Colorado and an MBA from the University of Chicago Booth School of Business.